0001193125-26-048776
SEC filingAmerican Well Corporation reported a net loss of $95.7 million for fiscal year 2025, with revenue of $249.3 million. The company generated a gross profit of $132.8 million (revenue of $249.3 million minus cost of revenue of $116.5 million), resulting in a gross margin of 53.3%. Operating loss was $105.3 million, driven by significant expenses in research and development ($72.9 million), sales and marketing ($43.3 million), and general and administrative ($88.0 million). The company used $66.0 million in operating cash flow but generated $17.1 million from investing activities primarily through divestiture proceeds. Total assets stood at $323.8 million with $182.3 million in cash and cash equivalents, while total liabilities were $76.0 million. The company maintained $247.8 million in stockholders' equity with an accumulated deficit of $2.06 billion.
American Well Corporation reported fiscal year 2025 results with revenue of $249.3 million and a net loss attributable to the company of $95.7 million. The company's operating loss was $105.3 million, reflecting significant investments in operations despite revenue generation. Comprehensive loss attributable to American Well Corporation was $92.0 million. The company reported basic and diluted net loss per share of $6.00 based on 16.0 million weighted-average common shares outstanding. Total costs and operating expenses amounted to $354.6 million, comprising cost of revenue ($116.5 million), research and development ($72.9 million), sales and marketing ($43.3 million), general and administrative ($88.0 million), and depreciation and amortization ($34.0 million).
The filing reports total revenue of $249.3 million for fiscal year 2025. The document indicates revenue includes amounts from related parties but does not provide segment breakdowns, geographic mix, or specific growth drivers. The revenue figure represents the company's total top-line performance for the period without further disaggregation in the provided data. No comparative prior period revenue figures are provided in the XBRL data or document text, preventing year-over-year growth rate calculations.
Gross profit was $132.8 million (revenue of $249.3 million minus cost of revenue of $116.5 million), resulting in a gross margin of 53.3%. Operating margin was negative 42.2% (operating loss of $105.3 million divided by revenue of $249.3 million). The cost structure shows significant investment in research and development ($72.9 million, representing 29.2% of revenue) and general and administrative expenses ($88.0 million, representing 35.3% of revenue). Sales and marketing expenses were $43.3 million (17.4% of revenue). Depreciation and amortization expense was $34.0 million (13.6% of revenue).
Net cash used in operating activities was $66.0 million, primarily driven by the net loss of $95.0 million adjusted for non-cash items including depreciation and amortization ($34.0 million), stock-based compensation ($22.0 million), and changes in working capital. Investing activities provided $17.1 million in cash, mainly from net proceeds from divestiture of $18.3 million. Financing activities provided $840,000. Total cash, cash equivalents, and restricted cash at period end was $539.3 million. The balance sheet shows total assets of $323.8 million including current assets of $246.7 million. Total liabilities were $76.0 million with current liabilities of $73.2 million. Stockholders' equity was $247.8 million with accumulated deficit of $2.06 billion.
The provided XBRL data and document content do not include management guidance, strategic priorities, or specific risk factors for future periods. No forward-looking statements, projections, or outlook commentary is present in the extracted financial data sections. The filing presents historical financial results for fiscal year 2025 without explicit discussion of future expectations, growth initiatives, or market conditions affecting upcoming periods.